Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.
UrzalJCimbronMMendonçaT, et al. Eosinophilic fasciitis (Shulman’s disease): review and comparative evaluation of seven patients. Reumatologia2019; 57(2): 85–90.
2.
MazoriDRFemiaANVleugelsRA.Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep2017; 19: 74.
3.
IhnH.Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int2019; 68(4): 437–439.
4.
TullRHooverWDIIIDe LucaJF, et al. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context2018; 7: 212529.
5.
EspinozaFJorgensenCPersYM.Efficacité du tocilizumab dans un cas de fasciite à eósinophiles. Rev du Rhum2015; 82: 414–415.
6.
KimSRCharosADamskyW, et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep2018; 4(5): 443–445.
7.
KankaarantaHIlmarinenPZhangX, et al. Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1. PLoS ONE2014; 9: e90298.
8.
KhannaDAgrawalHClementsPJ.Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford)2010; 49(6): 1184–1188.
9.
DrosouAKirsnerRSWelshE, et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg2003; 7(5): 382–386.
10.
TzaribachevNHolzerUSchedelJ, et al. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford)2008; 47(6): 930–932.
